Fusion Antibodies Share Discussion Threads

[luckyabbeygale] 05/2/2024 08:45

Lots of HE1 profit will end up here.

[luckyabbeygale] 01/2/2024 09:00

Fusion only slid back from 7.5p because of placing worries.
Now this has been addressed from the HMRC tax credit.
Every fall back from a rise is always replaced by a stronger rise the next time out.

[bigjock36] 01/2/2024 07:38

Excellent news good cash runway again to get the projects over the line

[gtc1508] 01/2/2024 07:05

280k R&D credit in - should boost the cash position for a while

[cbeadle] 31/1/2024 22:30

Absolutely 💯, it’s been quiet since the NCI announcement. If only they could list on NASDAQ they would return 10-20 fold in the blink of an eye!

[bigjock36] 31/1/2024 20:44

Anything to evidence cash flow being sorted and this is 10 p plus in a heartbeat

[cbeadle] 31/1/2024 16:44

On the way back up again. I wonder if some agreements are on the way?

[blackhorse23] 29/1/2024 15:32

https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097

[ken chung] 27/1/2024 09:33

Sell, sell, sell.Lemmings and mushrooms only.

[blackhorse23] 24/1/2024 09:46

Out now , and going to buy APH ( profit making health care company)

[bigjock36] 24/1/2024 09:05

Disagree entirely keep trying to scare people

[bones698] 23/1/2024 18:12

Very touch and go though . Do you really want to be running on fumes and then miss break even could spell disaster. Remember you need a years cash just to keep going as a going concern at results .
A fund raise looks almost a certainty here and until clarity in revenues etc become clearer it looks best to wait on the sidelines

[gtc1508] 23/1/2024 17:15

From Allenby capitals most recent research note in December 23:

typically around 50% until about a year ago).
As a result of its restructuring, Fusion's total cash cost base has been reduced to c.
£250k/month and we anticipate revenue to recover to around these levels by mid FY2025 (i.e. Summer of 2024). The cash position of £500k as of end September should also be expected to be boosted by the receipt of the FY23 R&D tax credit of c. £100k in early 2024.
On this basis, we model a cash reach until at least middle of CY 2024, although we note that the company would potentially be trading at close to cashflow breakeven at this point.

[clocktower] 23/1/2024 16:34

Nobby not another MIN your working on.🤣🤣; BEWARE of GNOMES!

[jaknife] 23/1/2024 16:30

I have no particular interest in FAB anymore, it's too small a company. But I would be interested to see any calculations that anyone has done of (a) what FAB's current monthly cash burn is, and (b) therefore what FAB's current cash position is.

Do people routinely do these sorts of calculations before investing?

JakNife

[nobbygnome] 23/1/2024 16:10

My impression was they hadn’t received the tax credit yet but I could be wrong. He implied this would be an amount to stave off a fundraise for a while and was not generally appreciated by the market.

I too am researching it with a view to buying in. I worked in the antibody field and know how difficult it is especially for small companies but there could be value here because of the low market cap. This is the sort of company where it could be useful for to PIs organise together to help them with finance.

[cbeadle] 23/1/2024 15:52

That would be a huge help to get them through Nobbygnome

[langland] 23/1/2024 15:52

263k is the amount of the tax credit in the last accounts. I would have thought the company should have received this by now.

[flashheart] 23/1/2024 15:50

I'm currently researching with a view to buying and would appreciate any feedback you're able/willing to share Nobby as indeed would others I dare say.

[nobbygnome] 23/1/2024 15:48

I should say I am currently researching the company and will be talking with a mutual friend who is an expert in this field.

[nobbygnome] 23/1/2024 15:44

I was at the Proactive talk and discovered I worked with Adrian about 20 years ago. We had a good discussion afterwards and wrt finance he said they had a chunky tax credit to come shortly. I don’t know if this has been discussed before but I can’t see it mentioned on a quick read of the last financial results